Literature DB >> 15366815

Infantile-onset glycogen storage disease type II (Pompe disease): report of a case with genetic diagnosis and pathological findings.

Yao-Tun Teng1, Wen-Jen Su, Jia-Wei Hou, Shiu-Feng Huang.   

Abstract

Glycogen storage disease type II (GSD-II), also known as Pompe disease, is a rare autosomial recessive disease due to deficiency of lysosomal acid alpha-glucosidase (GAA). The infantile-onset form is the most severe, and most patients present with hypotonia and cardiomyopathy in early infancy. We report on a typical case of Pompe disease in a patient who died at 8 months of age due to aspiration pneumonia and hypertrophic cardiomyopathy. Genetic studies showed deficient GAA activity and mutation of the GAA gene with Gly615Arg (exon 13, G1845A). On autopsy, glycogen had markedly accumulated in the liver, myocardium and skeletal muscle. The neurons of the anterior horn of the spinal cord and medulla were also involved, but the cortex was spared. These neurological-histologic findings may explain the clinical features of poor motor function, decreased deep tendon reflexes and lack of mental retardation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15366815

Source DB:  PubMed          Journal:  Chang Gung Med J        ISSN: 2072-0939


  29 in total

1.  Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice.

Authors:  Kai Qiu; Darin J Falk; Paul J Reier; Barry J Byrne; David D Fuller
Journal:  Mol Ther       Date:  2011-10-18       Impact factor: 11.454

Review 2.  Pompe disease gene therapy.

Authors:  Barry J Byrne; Darin J Falk; Christina A Pacak; Sushrusha Nayak; Roland W Herzog; Melissa E Elder; Shelley W Collins; Thomas J Conlon; Nathalie Clement; Brian D Cleaver; Denise A Cloutier; Stacy L Porvasnik; Saleem Islam; Mai K Elmallah; Anatole Martin; Barbara K Smith; David D Fuller; Lee Ann Lawson; Cathryn S Mah
Journal:  Hum Mol Genet       Date:  2011-04-25       Impact factor: 6.150

3.  Postmortem Findings and Clinical Correlates in Individuals with Infantile-Onset Pompe Disease.

Authors:  Loren D M Pena; Alan D Proia; Priya S Kishnani
Journal:  JIMD Rep       Date:  2015-03-13

Review 4.  Liver depot gene therapy for Pompe disease.

Authors:  Priya S Kishnani; Dwight D Koeberl
Journal:  Ann Transl Med       Date:  2019-07

Review 5.  An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond.

Authors:  Aditi Korlimarla; Jeong-A Lim; Priya S Kishnani; Baodong Sun
Journal:  Ann Transl Med       Date:  2019-07

6.  Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical Planning.

Authors:  Manuela Corti; Brian Cleaver; Nathalie Clément; Thomas J Conlon; Kaitlyn J Faris; Gensheng Wang; Janet Benson; Alice F Tarantal; Davis Fuller; Roland W Herzog; Barry J Byrne
Journal:  Hum Gene Ther Clin Dev       Date:  2015-09       Impact factor: 5.032

7.  Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice.

Authors:  Mai K Elmallah; Darin J Falk; Sushrusha Nayak; Roland A Federico; Milapjit S Sandhu; Amy Poirier; Barry J Byrne; David D Fuller
Journal:  Mol Ther       Date:  2013-12-12       Impact factor: 11.454

8.  Rapidly Progressive White Matter Involvement in Early Childhood: The Expanding Phenotype of Infantile Onset Pompe?

Authors:  A Broomfield; J Fletcher; P Hensman; R Wright; H Prunty; J Pavaine; S A Jones
Journal:  JIMD Rep       Date:  2017-07-20

9.  Identification of eight novel mutations of the acid alpha-glucosidase gene causing the infantile or juvenile form of glycogen storage disease type II.

Authors:  L Wan; C-C Lee; C-M Hsu; W-L Hwu; C-C Yang; C-H Tsai; F-J Tsai
Journal:  J Neurol       Date:  2008-05-06       Impact factor: 4.849

Review 10.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.